CIA
AMRX icon

Concurrent Investment Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Concurrent Investment Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
60,025
+391
+0.7% +$5.36K 0.01% 989
2026
Q1 		$741K Sell
59,634
-22,332
-27% -$300K 0.01% 1025
2025
Q4 		$1.03M Buy
81,966
+47,261
+136% +$541K 0.01% 819
2025
Q3 		$347K Buy
+34,705
New +$312K 0.01% 1086

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Concurrent Investment Advisors's AMRX Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 0.66% in Q2 2026, buying an estimated $5.36K and bringing the position to 60,025 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #989.

Concurrent Investment Advisors first reported a position in AMRX in Q3 2025 and has held it in 4 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Concurrent Investment Advisors held 60,025 shares of Amneal Pharmaceuticals worth $1.04M as of Q2 2026.
  • Concurrent Investment Advisors bought 391 Amneal Pharmaceuticals shares in Q2 2026, an estimated $5.36K.
  • Amneal Pharmaceuticals made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #989 holding.
  • Concurrent Investment Advisors first reported a position in Amneal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.